Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

143P - Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+ breast cancer. A systematic review and network meta-analysis (NMA)

Date

10 Sep 2022

Session

Poster session 01

Topics

Tumour Site

Breast Cancer

Presenters

Guillermo Villacampa Javierre

Citation

Annals of Oncology (2022) 33 (suppl_7): S55-S84. 10.1016/annonc/annonc1038

Authors

G. Villacampa Javierre1, T. Pascual2, A. Matikas3, A. Papakonstantinou4

Author affiliations

  • 1 Statistics Department, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, 8035 - Barcelona/ES
  • 2 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 3 K7 Oncology-pathology Department, Karolinska Institutet, 141 83 - Huddinge/SE
  • 4 Oncology Department, Karolinska Institutet and Vall D´Hebron Institute of Oncology (VHIO), 171 76 - Solna, Barcelona/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 143P

Background

Neoadjuvant therapy (NAT) is the recommended approach to early HER2+ breast cancer (BC). Anthracycline (ANTR)-polychemotherapy (CT) regimens have been the first choice but newer combinations with multiple anti-HER2 agents with or without ANTR have also shown efficacy. The questions of the optimal combination and whether ANTR could be omitted remain.

Methods

A systematic literature review in the Medline, Embase and Web of Science databases was performed.Randomised controlled trials (RCTs) evaluating NAT for HER2+ BC with at least one group with anti-HER2 targeted treatment, were selected. Primary endpoint was pathological complete response (pCR) and secondary endpoints were event-free survival (EFS), overall survival (OS) and toxicity incidence. A frequentist NMA was performed using random-effect models for the estimation of odds-ratio (OR) and hazard ratio (HR) along with the 95% confidence interval (95% CI).

Results

The literature search identified 3384 records; 67 articles corresponding to 48 RCTs met the eligibility criteria and additional 4 articles (3 RCTs) published during data analysis were included. A total of 16,245 patients with early HER2+ BC were included in the global network. For the pCR endpoint (n=10,906), three combinations performed significantly better than trastuzumab (TRA) + CT: i) pertuzumab (PER) + TRA + CT, ii) single T-DM1 and iii) Tyrosine Kinase Inhibitors (TKI) + TRA + CT. In the EFS analysis (n=6,657), PER + TRA + CT and TKI + TRA + CT demonstrated superiority against single T-DM1 (HR: 0.45; 0.26-0.78 and HR: 0.41; 0.19-0.87, respectively). In a more aggregated analysis, the combination of dual anti-HER2 + CT associated with significantly better EFS and OS than i) dual anti-HER2 alone, ii) anti-HER2 + CT and iii) single T-DM1. Comparison of regimens with or without ANTR demonstrated no significant differences in pCR rates, but all estimations were in favour of the non-ANTR group. There was no difference in EFS either (HR: 1.00, 0.62 - 1.62). Similar safety profiles were observed with or without ANTR, with the exception of higher risk of LVEF drop with ANTR and dual anti-HER2 (PRE + TRA).

Conclusions

The combination of dual anti-HER2 + CT provides the best efficacy results. Additionally, this study provides evidence that anthracyclines can be safely omitted in early HER2+ BC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

G. Villacampa Javierre: Financial Interests, Personal, Invited Speaker, Invited speaker in a course: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Invited speaker in an internal training: Pierre Fabrer, GSK. T. Pascual: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Lilly. A. Matikas: Non-Financial Interests, Advisory Role: Veracyte. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.